XML 30 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Revenue $ 622 $ 240 $ 934
Operating expenses:      
Research and development (including amounts with related parties) 232,366 248,149 195,958
Selling, general and administrative (including amounts with related parties) 129,620 102,708 135,256
Impairment of intangible assets 886 681 0
Total operating expenses 362,872 351,538 331,214
Loss from operations (362,250) (351,298) (330,280)
Other expense, net:      
Interest and investment income (loss), net 1,131 (3,090) (4,100)
Interest expense (including amounts with related parties) (129,198) (63,515) (14,849)
Loss on equity method investment (7,549) (12,107) (803)
Change in fair value of warrant liabilities (47,600) 13,460 0
Change in fair value of related-party convertible note (36,203) 0 0
Other (expense) income, net (including amounts with related parties) (2,223) (736) 193
Total other expense, net (221,642) (65,988) (19,559)
Loss before income taxes and noncontrolling interests (583,892) (417,286) (349,839)
Income tax benefit (expense) 40 (34) (9)
Net loss (583,852) (417,320) (349,848)
Net loss attributable to noncontrolling interests, net of tax (656) (753) (3,058)
Net loss attributable to ImmunityBio common stockholders $ (583,196) $ (416,567) $ (346,790)
Net loss per ImmunityBio common share - basic (in dollars per share) $ (1.15) $ (1.04) $ (0.89)
Net loss per ImmunityBio common share - diluted (in dollars per share) $ (1.15) $ (1.04) $ (0.89)
Weighted-average number of common shares used in computing net loss per share – basic (in shares) 508,635,592 399,900,374 389,234,156
Weighted-average number of common shares used in computing net loss per share – diluted (in shares) 508,635,592 399,900,374 389,234,156